Clinical and pharmacological differences in early- versus late-onset Parkinson's disease
- PMID: 9159719
- DOI: 10.1002/mds.870120303
Clinical and pharmacological differences in early- versus late-onset Parkinson's disease
Abstract
We evaluated whether patients with early-onset Parkinson's disease (EOPD) have a different clinical profile and pharmacological response than those with late-onset disease (LOPD). We performed a retrospective analysis and an acute pharmacological challenge with L-Dopa in 34 EOPD (age at onset between 21 and 40 years) and 34 LOPD (onset after age 60) patients. All patients completed a structured questionnaire cross-checked against medical record charts and underwent an acute levodopa test. Most significant differences were in the mode of onset, time of diagnosis, and degree of initial improvement. We did not observe differences with regard to motor fluctuations. The acute levodopa test showed no differences in latency to response onset between groups. However, the magnitude of the response was greater and the duration shorter in EOPD patients. Younger patients had greater reductions in bradykinesia scores, whereas posture/gait symptomatology was less responsive in older patients. The type and severity of dyskinesias also differed significantly between groups. Our findings suggest that central pharmacokinetics, pharmacodynamics, and possibly, nondopaminergic systems play a role in the age-related differences observed in Parkinson's disease.
Similar articles
-
Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.J Clin Neurosci. 2009 Aug;16(8):1034-7. doi: 10.1016/j.jocn.2008.10.015. Epub 2009 May 9. J Clin Neurosci. 2009. PMID: 19428256
-
Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.Parkinsonism Relat Disord. 2005 May;11(3):151-5. doi: 10.1016/j.parkreldis.2004.10.002. Parkinsonism Relat Disord. 2005. PMID: 15823479
-
[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].Rev Neurol (Paris). 2001 May;157(5):507-14. Rev Neurol (Paris). 2001. PMID: 11438770 French.
-
[Physiopathology of the dyskinesias induced by L-dopa].Rev Neurol. 1997 Aug;25 Suppl 2:S151-6. Rev Neurol. 1997. PMID: 9280682 Review. Spanish.
-
[Treatment and prognosis of juvenile parkinsonism--L-dopa responsiveness].Nihon Rinsho. 1997 Jan;55(1):101-5. Nihon Rinsho. 1997. PMID: 9014430 Review. Japanese.
Cited by
-
Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA.Psychopharmacology (Berl). 2012 Sep;223(2):191-7. doi: 10.1007/s00213-012-2706-0. Epub 2012 Apr 13. Psychopharmacology (Berl). 2012. PMID: 22526536
-
Framework for identifying drug repurposing candidates from observational healthcare data.JAMIA Open. 2020 Dec 31;3(4):536-544. doi: 10.1093/jamiaopen/ooaa048. eCollection 2020 Dec. JAMIA Open. 2020. PMID: 33623890 Free PMC article.
-
Therapy of Parkinson's Disease Subtypes.Neurotherapeutics. 2020 Oct;17(4):1366-1377. doi: 10.1007/s13311-020-00894-7. Neurotherapeutics. 2020. PMID: 32749651 Free PMC article. Review.
-
Parkinson's disease and healthy aging: independent and interacting effects on action selection.Hum Brain Mapp. 2010 Dec;31(12):1886-99. doi: 10.1002/hbm.20979. Epub 2010 Feb 16. Hum Brain Mapp. 2010. PMID: 20162604 Free PMC article.
-
Levodopa-induced dyskinesia in early-onset Parkinson's disease (EOPD) associates with glucocerebrosidase mutation: A next-generation sequencing study in EOPD patients in Thailand.PLoS One. 2023 Oct 31;18(10):e0293516. doi: 10.1371/journal.pone.0293516. eCollection 2023. PLoS One. 2023. PMID: 37906549 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical